Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis

Journal of Infection

Volumn 76, Issue 4, 2018, Pages 342-347

  De la Calle, C ^a   Ternavasio de la Vega, H G ^b   Morata, L ^a   Marco, F ^a   Cardozo, C ^a   Garcia Vidal C ^a   Del Rio, A ^a   Cilloniz, C ^c   Torres, A ^c   Martinez J A ^a   Mensa, J ^a   Soriano, A ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bacteraemia; Combination therapy; Mortality; Pneumococcal pneumonia; Propensity score

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; MACROLIDE;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY RATE; NONHUMAN; OBSERVATIONAL STUDY; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEPTIC SHOCK; SPAIN; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; BACTEREMIA; BLOOD; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED INFECTION; HOSPITALIZATION; MORTALITY; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PROPENSITY SCORE; PROSPECTIVE STUDIES;

EID: 85041601465     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2018.01.003     Document Type: Article

References (41)

1. Broulette, J., Yu, H., Pyenson, B., Iwasaki, K., Sato, R., The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits 6:8 (2013), 494–503.
2. Lim, W.S., Baudouin, S.V., George, R.C., Hill, A.T., Jamieson, C., Le Jeune, I., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64:Suppl 3 (2009), iii1–ii55.
3. Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect 17:Suppl 6 (2011), E1–59.
4. Nie, W., Li, B., Xiu, Q., β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother 69:6 (2014), 1441–1446.
5. Postma, D.F., van Werkhoven, C.H., van Elden, L.J., Thijsen, S.F., Hoepelman, A.I., Kluytmans, J.A., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372:14 (2015), 1312–1323.
6. Bordon, J.M., Fernandez-Botran, R., Wiemken, T.L., Peyrani, P., Uriarte, S.M., Arnold, F.W., et al. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. Infection 43:6 (2015), 729–738.
7. Garcia-Vidal, C., Fernández-Sabé N., Carratalà J., Díaz, V., Verdaguer, R., Dorca, J., et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 32 (2008), 733–739.
8. Waterer, G.W., Somes, G.W., Wunderink, R.G., Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:15 (2001), 1837–1842.
9. Weiss, K., Low, D.E., Cortes, L., Beaupre, A., Gauthier, R., Gregoire, P., et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 11:8 (2004), 589–593.
10. Dwyer, R., Ortqvist, A., Aufwerber, E., Henriques Normark, B., Marrie, T.J., Mufson, M.A., et al. Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 25:8 (2006), 518–521.
11. Naucler, P., Darenberg, J., Morfeldt, E., Ortqvist, A., Henriques Normark, B., Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 68:6 (2013), 571–579.
12. McCabe, W.R., Jackson, G.G., Gram-negative bacteremia: II. clinical, laboratory, and therapeutic observations. Arch Intern Med 110 (1962), 856–864.
13. Rosenbaum, P.R., Rubin, D., Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79 (1984), 516–524.
14. Ternavasio-de la Vega, H.G., Mateos-Díaz, A.M., Martínez, J.A., Almela, M., Cobos-Trigueros, N., Morata, L., et al. A propensity score analysis shows that empirical treatment with linezolid does not increase the thirty-day mortality rate in patients with gram-negative bacteremia. Antimicrob Agents Chemother 58:12 (2014), 7025–7031.
15. Austin, P.C., Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:2 (2011), 150–161.
16. Austin, P.C., Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 134:5 (2007), 1128–1135.
17. Austin, P.C., The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med 29:20 (2010), 2137–2148.
18. Fernández-Ruiz, M., Aguado, J.M., Almirante, B., Lora-Pablos, D., Padilla, B., Puig-Asensio, M., et al. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis 58:10 (2014), 1413–1421.
19. Thoemmes, F.J., Kim, E.S., A systematic review of propensity score methods in the social sciences. Multivariate Behav Res 46:1 (2011), 90–118.
20. Mufson, M.A., Stanek, R.J., Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. Am J Med 107:1A (1999), 34S–43S.
21. Martínez, J.A., Horcajada, J.P., Almela, M., Marco, F., Soriano, A., García, E., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:4 (2003), 389–395.
22. Garin, N., Genné D., Carballo, S., Chuard, C., Eich, G., Hugli, O., et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 174:12 (2014), 1894–1901.
23. Rodrigo, C., McKeever, T.M., Woodhead, M., Lim, W.S., British Thoracic Society. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 68:5 (2013), 493–495.
24. Tempera, G., Furneri, P.M., Ferranti, C., Genovese, C., Ripa, S., Ungheri, S., et al. In vitro activity of cefditoren versus other antibiotics against S. pneumoniae clinical strains isolated in Italy. Int J Immunopathol Pharmacol 23:3 (2010), 833–840.
25. Rodríguez, A., Mendia, A., Sirvent, J.M., Barcenilla, F., de la Torre-Prados, M.V., Solé-Violán, J., et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 35:6 (2007), 1493–1498.
26. Mortensen, E.M., Restrepo, M.I., Anzueto, A., Pugh, J., The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care, 10(1), 2005, R8.
27. Vardakas, K.Z., Trigkidis, K.K., Falagas, M.E., Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect 23:4 (2017), 234–241.
28. Drago, L., Nicola, L., Rodighiero, V., Larosa, M., Mattina, R., De Vecchi, E., Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae. J Antimicrob Chemother 66:4 (2011), 845–849.
29. Johansen, H.K., Jensen, T.G., Dessau, R.B., Lundgren, B., Frimodt-Moller, N., Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother 46:6 (2000), 973–980.
30. Ortega, M., Marco, F., Soriano, A., Gómez, J., Almela, M., Mensa, J., In vitro antagonism between beta-lactam and macrolide in Streptococcus pneumoniae: how important is the antibiotic order?. Int J Antimicrob Agents 24:2 (2004), 178–180.
31. Ichiyama, T., Nishikawa, M., Yoshitomi, T., Hasegawa, S., Matsubara, T., Hayashi, T., et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 45:1 (2001), 44–47.
32. Choi, J.H., Song, M.J., Kim, S.H., Choi, S.M., Lee, D.G., Yoo, J.H., et al. Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Chemother 47:12 (2003), 3704–3707.
33. Calbo, E., Alsina, M., Rodríguez-Carballeira, M., Lite, J., Garau, J., Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 52:7 (2008), 2395–2402.
34. Shinkai, M., Henke, M.O., Rubin, B.K., Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 117:3 (2008), 393–405.
35. Kovaleva, A., Remmelts, H.H., Rijkers, G.T., Hoepelman, A.I., Biesma, D.H., Oosterheert, J.J., Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J Antimicrob Chemother 67:3 (2012), 530–540.
36. Anderson, R., Steel, H.C., Cockeran, R., Smith, A.M., von Gottberg, A., de Gouveia, L., et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother 59:2 (2007), 224–229.
37. Fukuda, Y., Yanagihara, K., Higashiyama, Y., Miyazaki, Y., Hirakata, Y., Mukae, H., et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 27:5 (2006), 1020–1025.
38. Majhi, A., Adhikary, R., Bhattacharyya, A., Mahanti, S., Bishayi, B., Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin. Antimicrob Agents Chemother 58:9 (2014), 5164–5180.
39. Rubins, J.B., Charboneau, D., Paton, J.C., Mitchell, T.J., Andrew, P.W., Janoff, E.N., Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest 95:1 (1995), 142–150.
40. Carapetis, J.R., Jacoby, P., Carville, K., Ang, S.J., Curtis, N., Andrews, R., Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 59:3 (2014), 358–365.
41. Gutiérrez, F., Masiá M., Rodríguez, J.C., Mirete, C., Soldán, B., Padilla, S., et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 24:6 (2005), 377–383.